These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 23690094)

  • 1. Summarizing the incidence of adverse events using volcano plots and time intervals.
    Zink RC; Wolfinger RD; Mann G
    Clin Trials; 2013; 10(3):398-406. PubMed ID: 23690094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Graphical approaches to the analysis of safety data from clinical trials.
    Amit O; Heiberger RM; Lane PW
    Pharm Stat; 2008; 7(1):20-35. PubMed ID: 17323410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Data mining and statistically guided clinical review of adverse event data in clinical trials.
    Southworth H; O'Connell M
    J Biopharm Stat; 2009 Sep; 19(5):803-17. PubMed ID: 20183445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statistical methods to analyze adverse events data of randomized clinical trials.
    Siddiqui O
    J Biopharm Stat; 2009 Sep; 19(5):889-99. PubMed ID: 20183450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developing tools for the safety specification in risk management plans: lessons learned from a pilot project.
    Cooper AJ; Lettis S; Chapman CL; Evans SJ; Waller PC; Shakir S; Payvandi N; Murray AB
    Pharmacoepidemiol Drug Saf; 2008 May; 17(5):445-54. PubMed ID: 18383441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of safety data in clinical trials using a recurrent event approach.
    Gong Q; Tong B; Strasak A; Fang L
    Pharm Stat; 2014; 13(2):136-44. PubMed ID: 24519954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interpreting sexually transmissible infection prevention trials by adjusting for the magnitude of exposure.
    Wilson DP
    Clin Trials; 2010 Feb; 7(1):36-43. PubMed ID: 20007407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of incidence of rare events.
    Lane PW
    Stat Methods Med Res; 2013 Apr; 22(2):117-32. PubMed ID: 22218366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The number remaining at risk: an adjunct to the number needed to treat.
    Massel D; Cruickshank MK
    Can J Cardiol; 2002 Mar; 18(3):254-8. PubMed ID: 11907613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introduction--databases and the assessment of complications associated with the treatment of patients with congenital cardiac disease.
    Jacobs JP
    Cardiol Young; 2008 Dec; 18 Suppl 2():1-37. PubMed ID: 19063774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial assessing the efficacy of fluconazole in the treatment of pediatric tinea capitis.
    Foster KW; Friedlander SF; Panzer H; Ghannoum MA; Elewski BE
    J Am Acad Dermatol; 2005 Nov; 53(5):798-809. PubMed ID: 16243128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Confidence intervals for an exposure adjusted incidence rate difference with applications to clinical trials.
    Liu GF; Wang J; Liu K; Snavely DB
    Stat Med; 2006 Apr; 25(8):1275-86. PubMed ID: 16138360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When to stop treatment arms in a clinical trial assessing time to event with more than two arms against a common control.
    Grobler AC; Carrara HR; Mwambi HG; Parker RA
    Eval Health Prof; 2007 Sep; 30(3):284-99. PubMed ID: 17693620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple events of fractures and cardiovascular and thromboembolic disease following prostate cancer diagnosis: results from the population-based PCBaSe Sweden.
    Van Hemelrijck M; Garmo H; Holmberg L; Stattin P; Adolfsson J
    Eur Urol; 2012 Apr; 61(4):690-700. PubMed ID: 21945719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statistical analysis and design for estimating accuracy in clinical-center classification of cause-specific clinical events in clinical trials.
    Yan G; Greene T
    Clin Trials; 2011 Oct; 8(5):571-80. PubMed ID: 22013170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparisons between ITT and treatment emergent adverse event analyses.
    Quan H; Sun Q; Zhang J; Shih WJ
    Stat Med; 2008 Nov; 27(26):5356-76. PubMed ID: 18618431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of short-term preventive frovatriptan: a combined analysis.
    MacGregor EA; Brandes JL; Silberstein S; Jeka S; Czapinski P; Shaw B; Pawsey S
    Headache; 2009 Oct; 49(9):1298-314. PubMed ID: 19788471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.